- Home
- KNRX vs BLRX Comparison
KNRX vs BLRX Comparison
Compare KNRX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNRX | BLRX |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.0M |
| IPO Year | 2023 | 2010 |
Fundamental Metrics
Financial Performance| Metric | KNRX | BLRX |
|---|---|---|
| Price | $1.17 | $2.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 26.4K | 19.3K |
| Earning Date | 06-12-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $2.15 |
| 52 Week High | $3.45 | $4.56 |
Technical Indicators
Market Signals| Indicator | KNRX | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 89.37 | 41.19 |
| Support Level | $0.35 | $2.18 |
| Resistance Level | $1.46 | $2.51 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 75.71 | 0.00 |
Price Performance
Historical ComparisonAbout KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.